KR880007079A - 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법 - Google Patents
레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법 Download PDFInfo
- Publication number
- KR880007079A KR880007079A KR870014383A KR870014383A KR880007079A KR 880007079 A KR880007079 A KR 880007079A KR 870014383 A KR870014383 A KR 870014383A KR 870014383 A KR870014383 A KR 870014383A KR 880007079 A KR880007079 A KR 880007079A
- Authority
- KR
- South Korea
- Prior art keywords
- retrovirus
- pharmaceutical composition
- ene
- therapeutic agent
- dioxythymidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 단독의 또는 희석제와 혼합된, 또는 의약의 형태의 3′-디옥시티미딘-2′-엔으로 되어 있는 것을 특징으로 하는 레트로비루스로 감염된 온혈동물의 치료제.
- 제1항에 있어서, 레트로비루스가 물로니 쥐 백혈병 비루스인 것을 특징으로 하는 치료제.
- 제1항에 있어서, 레트로비루스가 HTLV III/LAV인 것을 특징으로 하는 치료제.
- 제1항에 있어서, 정맥내 투여시는 일당 체중 kg당 0.01 내지 10mg양의 3′-디옥시티미딘-2′-엔이 사용되는 것을 특징으로 하는 치료제.
- 고체, 액체 또는 액화기체 희석제와 혼합된 항레트로비루스 유효량의 3′-디옥시티미딘-2′-엔을 활성성분으로 포함하는 것을 특징으로 하느 약학조성물.
- 제5항에 있어서, 상기 활성성분 0.5 내지 90%를 포함하는 것을 특징으로 하는 약학조성물.
- 제5항에 있어서, 스테릴 생리학적 등침투성 수용액의 형태로 구성되는 것을 특징으로 하는 약학조성물.
- 제5항에 있어서, 상기 활성성분 0.5 내지 90%를 포함하는 것을 특징으로 하는 약학조성물.
- 항 레트로비루스 유효량의 3′-디옥시티미딘-2′-엔 및 불활성 약학용 딤체로 구성되는 것을 특징으로 하는 사용단위형의 의약.
- 제9항에 있어서, 의약이 정제, 환약, 당의정, 캡슐, 캡레트, 앰플 또는 좌약의 형으로 구성되는 것을 특징으로 하는 의약.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US942666 | 1986-12-17 | ||
US942,666 | 1986-12-17 | ||
US06/942,666 US4978655A (en) | 1986-12-17 | 1986-12-17 | Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880007079A true KR880007079A (ko) | 1988-08-26 |
KR960000433B1 KR960000433B1 (ko) | 1996-01-06 |
Family
ID=25478432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870014383A KR960000433B1 (ko) | 1986-12-17 | 1987-12-17 | 레트로비루스에 감염된 환자치료에 사용되는 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 항바이러스 조성물 |
Country Status (22)
Country | Link |
---|---|
US (1) | US4978655A (ko) |
EP (1) | EP0273277B1 (ko) |
JP (1) | JPH07116041B2 (ko) |
KR (1) | KR960000433B1 (ko) |
AT (1) | ATE77554T1 (ko) |
AU (1) | AU593405B2 (ko) |
CA (1) | CA1293447C (ko) |
DE (1) | DE3780016T2 (ko) |
DK (1) | DK174627B1 (ko) |
EG (1) | EG19157A (ko) |
ES (1) | ES2038650T3 (ko) |
FI (1) | FI875544A (ko) |
GR (1) | GR3005691T3 (ko) |
HK (1) | HK55896A (ko) |
IE (1) | IE60866B1 (ko) |
IL (1) | IL84790A (ko) |
LU (1) | LU88822I2 (ko) |
NL (1) | NL960024I2 (ko) |
NZ (1) | NZ222935A (ko) |
PH (1) | PH26380A (ko) |
PT (1) | PT86346B (ko) |
ZA (1) | ZA877171B (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175292A (en) * | 1988-01-20 | 1992-12-29 | Regents Of The University Of Minnesota | Intermediates for the preparation of dideoxycarbocyclic nucleosides |
US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
FI95269C (fi) * | 1989-05-15 | 1996-01-10 | Squibb Bristol Myers Co | 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja |
US6207650B1 (en) | 1989-05-15 | 2001-03-27 | Bristol-Myers Squibb Company | Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine |
US5608048A (en) * | 1995-06-05 | 1997-03-04 | Bristol-Myers Squibb Company | d4 T polymorphic Form 1 process |
US5840711A (en) * | 1995-06-21 | 1998-11-24 | University Of Kentucky Research Foundation | Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome |
CA2189097A1 (en) | 1995-11-15 | 1997-05-16 | Pin-Fang Lin | Composition and method of treating retroviral infection |
US5719132A (en) * | 1996-06-27 | 1998-02-17 | Bristol-Myers Squibb Company | Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil |
WO2000016625A1 (en) * | 1998-09-23 | 2000-03-30 | University Of Kentucky Research Foundation | Antiviral drug compositions containing lithium inorganic salts |
NZ522250A (en) | 2000-03-30 | 2004-09-24 | Bristol Myers Squibb Co | Sustained release beadlets containing stavudine stabilised by magnesium stearate |
EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
BRPI0407374A (pt) | 2003-02-19 | 2006-01-10 | Univ Yale | Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv |
US20040200730A1 (en) * | 2003-04-14 | 2004-10-14 | Kyo Jibiki | Hydrometallurgical copper recovery process |
ATE505196T1 (de) | 2004-07-27 | 2011-04-15 | Gilead Sciences Inc | Nukleosid phosphonat konjugate als anti hiv mittel |
AP2008004389A0 (en) * | 2005-08-31 | 2008-04-30 | Cipla Ltd | Pharmaceutical combinations containing lamivudine,stavudine,stavudine and navirapine |
CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
MX2017000026A (es) | 2014-07-11 | 2017-05-01 | Gilead Sciences Inc | Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih). |
US20180263985A1 (en) | 2015-09-15 | 2018-09-20 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3322747A (en) * | 1965-04-01 | 1967-05-30 | Merck & Co Inc | Thionocarbonate nucleosides |
US3817982A (en) * | 1971-12-29 | 1974-06-18 | Syntex Inc | 2{40 ,3{40 -unsaturated nucleosides and method of making |
GB1523865A (en) * | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
JPS5943550B2 (ja) * | 1975-08-29 | 1984-10-23 | 田辺製薬株式会社 | 不飽和ヌクレオシドの製法 |
DE3515870A1 (de) * | 1985-05-03 | 1986-11-06 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 5-fluortoluol-2,4-disulfochlorid |
US4710492A (en) * | 1986-06-23 | 1987-12-01 | Yale University | 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses |
NL8700089A (nl) * | 1987-01-15 | 1988-08-01 | Stichting Rega V Z W | Therapeutische toepassing van dideoxythymidine en dideoxythymidineen. |
DE3806633A1 (de) * | 1987-09-01 | 1989-03-09 | Bayer Ag | Antivirales mittel |
JP2648329B2 (ja) * | 1987-09-18 | 1997-08-27 | エフ・ホフマン−ラ ロシュ アーゲー | エイズの予防または治療用医薬組成物 |
SE8704298D0 (sv) * | 1987-11-03 | 1987-11-03 | Astra Ab | Compounds for use in therapy |
JPH0227782A (ja) * | 1988-07-15 | 1990-01-30 | Hikari Gijutsu Kenkyu Kaihatsu Kk | 半導体発光素子 |
JPH0438727A (ja) * | 1990-06-04 | 1992-02-07 | Sharp Corp | 光学式ピックアップ装置の対物レンズ塵埃付着防止機構 |
-
1986
- 1986-12-17 US US06/942,666 patent/US4978655A/en not_active Expired - Lifetime
-
1987
- 1987-09-23 ZA ZA877171A patent/ZA877171B/xx unknown
- 1987-09-29 PH PH35869A patent/PH26380A/en unknown
- 1987-10-07 EG EG57787A patent/EG19157A/xx active
- 1987-10-23 DK DK198705570A patent/DK174627B1/da not_active IP Right Cessation
- 1987-11-06 AU AU80900/87A patent/AU593405B2/en not_active Expired
- 1987-11-24 JP JP62294251A patent/JPH07116041B2/ja not_active Expired - Lifetime
- 1987-11-30 IE IE324587A patent/IE60866B1/en not_active IP Right Cessation
- 1987-12-02 CA CA000553354A patent/CA1293447C/en not_active Expired - Lifetime
- 1987-12-11 EP EP87118407A patent/EP0273277B1/en not_active Expired - Lifetime
- 1987-12-11 PT PT86346A patent/PT86346B/pt unknown
- 1987-12-11 ES ES198787118407T patent/ES2038650T3/es not_active Expired - Lifetime
- 1987-12-11 IL IL84790A patent/IL84790A/xx not_active IP Right Cessation
- 1987-12-11 LU LU88822C patent/LU88822I2/fr unknown
- 1987-12-11 AT AT87118407T patent/ATE77554T1/de active
- 1987-12-11 DE DE8787118407T patent/DE3780016T2/de not_active Expired - Lifetime
- 1987-12-15 NZ NZ222935A patent/NZ222935A/xx unknown
- 1987-12-16 FI FI875544A patent/FI875544A/fi not_active Application Discontinuation
- 1987-12-17 KR KR1019870014383A patent/KR960000433B1/ko not_active IP Right Cessation
-
1992
- 1992-09-14 GR GR920402023T patent/GR3005691T3/el unknown
-
1996
- 1996-03-28 HK HK55896A patent/HK55896A/xx not_active IP Right Cessation
- 1996-10-07 NL NL960024C patent/NL960024I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
NL960024I2 (nl) | 1997-06-02 |
AU593405B2 (en) | 1990-02-08 |
CA1293447C (en) | 1991-12-24 |
ES2038650T3 (es) | 1993-08-01 |
FI875544A (fi) | 1988-06-18 |
LU88822I2 (fr) | 1997-01-06 |
DK557087D0 (da) | 1987-10-23 |
DE3780016T2 (de) | 1992-12-24 |
ZA877171B (en) | 1988-03-24 |
DK557087A (da) | 1988-06-18 |
PT86346A (en) | 1988-01-01 |
PT86346B (pt) | 1990-11-07 |
NL960024I1 (nl) | 1996-12-02 |
GR3005691T3 (ko) | 1993-06-07 |
PH26380A (en) | 1992-06-01 |
DE3780016D1 (de) | 1992-07-30 |
KR960000433B1 (ko) | 1996-01-06 |
DK174627B1 (da) | 2003-07-28 |
EP0273277A3 (en) | 1989-09-13 |
IL84790A (en) | 1993-03-15 |
IE873245L (en) | 1988-06-17 |
ATE77554T1 (de) | 1992-07-15 |
FI875544A0 (fi) | 1987-12-16 |
JPS63215632A (ja) | 1988-09-08 |
IL84790A0 (en) | 1988-05-31 |
AU8090087A (en) | 1988-06-23 |
EP0273277B1 (en) | 1992-06-24 |
JPH07116041B2 (ja) | 1995-12-13 |
EP0273277A2 (en) | 1988-07-06 |
NZ222935A (en) | 1990-09-26 |
US4978655A (en) | 1990-12-18 |
IE60866B1 (en) | 1994-08-24 |
EG19157A (en) | 1994-09-29 |
HK55896A (en) | 1996-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880007079A (ko) | 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법 | |
ES2076279T3 (es) | Medicamentos que, como principio activo, contienen acidos carboxilicos con contenido en azufre, asi como su empleo para combatir retrovirus. | |
KR900701282A (ko) | 심장 또는 뇌의 허혈성 질환의 치료, 예방제 | |
JPS6425A (en) | Medicinal composition for treating hiv infection containing dsrna and reverse transcriptase inhibitor | |
KR920702216A (ko) | 아세틸 d-카르니틴의 녹내장 치료에의 용도 | |
AU1935788A (en) | A process for producing an administration and/or dosage form for medically active ingredients of drugs | |
KR910700045A (ko) | Hiv 감염 관련 질병의 치료 | |
Kemper et al. | Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex | |
DE69322251D1 (de) | Medizinische zusammensetzung | |
KR970025615A (ko) | 암 전이 억제제 | |
KR950007848A (ko) | (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법 | |
KR880007074A (ko) | 의약품 | |
Cornbleet | SULFOXONE (DIASONE®) SODIUM FOR DERMATITIS HERPETIFORMIS | |
ES2139842T3 (es) | Uso de la melatonina para tratar a pacientes que sufren drogodependencia. | |
KR970032872A (ko) | 아세틸살리실산을 함유하는 피부 손상 처치용 약물 | |
KR890004705A (ko) | 항바이러스성 제제 | |
KR970705563A (ko) | 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent) | |
KR920703112A (ko) | 의약품 조성물 | |
KR890009401A (ko) | 바이러스를 억제시키는 방법 | |
FR2694693B1 (fr) | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. | |
KR860003018A (ko) | 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법 | |
KR890006665A (ko) | 항-hiv 활성, 3'-아지도-2,6-디아미노푸린-2',3'-디데옥시리보사이드 | |
BR0007627A (pt) | Mutações de hiv-1 selecionadas por beta-2', 3' -didehidro-2', 3' -didesóxi-5-fluorocitidina | |
KR900701301A (ko) | 후천성 면역 결핍증과 연관된 골수억제증의 치료방법 | |
KR910004190A (ko) | 온단세트론의 신규 의학 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20010104 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |